Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431312 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects
A Phase 1 study, sponsored by Inovio Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
NCT02431312 is a Phase 1 study that has completed, run by Inovio Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT02431312, a Phase 1 study, has completed, sponsored by Inovio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
Study Summary
This was an open-label study that evaluated the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen \[HBsAg\] and Hepatitis B core antigen \[HBcAg\]) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 90 (ninety) nucleos(t)ide analogue treated participants.
Interventions
- BIOLOGICAL INO-1800
- BIOLOGICAL INO-9112
- DRUG Nucleos(t)ide Analogue Treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2015-01-12 |
| Est. Completion | 2018-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431312
The ClinicalTrials.gov registry entry for NCT02431312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inovio Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which INO-1800 is the first listed.
NCT02431312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431312 about?
NCT02431312 is a clinical study titled "Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B Subjects". This was an open-label study that evaluated the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding Hepatitis B surface antigen \[HBsAg\] and Hepatitis B core antigen \[HBcAg\]) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electro...
What is the current status of trial NCT02431312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2015-01-12. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02431312?
The interventions under investigation include: INO-1800 (BIOLOGICAL), INO-9112 (BIOLOGICAL), Nucleos(t)ide Analogue Treatment (DRUG).
Who is sponsoring clinical trial NCT02431312?
This trial is sponsored by Inovio Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.